Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Vectus Biosystems shareholders approve all AGM resolutions as company advances VB0004 partnering strategy

VBS: $0.079 -1.25% · MC: $4M

Vectus Biosystems says it is prioritising idiopathic pulmonary fibrosis for lead drug candidate VB0004 and is building patient data to support its intended partnering strategy; the supplied CEO address is truncated before its full outlook is provided. The company also reported lower operating costs, a recent placement and an R&D tax rebate, while all AGM resolutions were passed, including approvals for a placement facility and employee incentive plan.

Source announcements: 2026-10-28 09:39 to 2026-10-28 14:45 Sydney time
Story updated 2026-10-28 14:50 Sydney time
Sources2026 AGM PresentationsResults of 2026 AGM
Comments